SynthesisFrontiers in medicine2025
Comparison of tegoprazan-based and proton pump inhibitor-based regimens for
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and Safety of Tegoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials.Journal of gastroenterology and hepatology · 2026Pooled it
- Efficacy and Safety of Tegoprazan inPharmaceuticals (Basel, Switzerland) · 2026Review
- Differences and trends in worldwide clinical guidelines forTranslational gastroenterology and hepatology · 2026Review
- Comparative effectiveness of genotype-guided and empirical bismuth-containing quadruple therapy forFrontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim: Tegoprazan (TEG) is a novel potassium-competitive acid blocker (P-CAB) that provides long-lasting acid-suppressing effects. The role of TEG-based Methods: We conducted a comprehensive search across multiple databases. Studies comparing Results: A total of eight studies involving 4,640 patients were included. Based on intention-to-treat (ITT) analyses, the overall eradication rate (78.6% vs. 76.6%; odds ratio [OR] = 1.08, 95% CI: 0.93-1.24; Conclusion: TEG-based Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024629665.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.